4basebio Plc has released its final results for the financial year ended 31 December 2023, along with a notice of the annual general meeting to be held on 28 June 2024. The company has reported several highlights, including the first sale of HQ synthetic DNA batch, the first order for GMP synthetic DNA, and the filing of six novel patent applications. Additionally, the company delivered over 25 customer projects during 2023.
4basebio Plc, a technology company based in Cambridge, UK, is a market leader in the development and commercialization of large-scale manufacture of synthetic DNA and nanoparticle delivery solutions. The company's customers are active in the cell & gene therapy and vaccine markets, across mRNA therapeutics and vaccines, AAV, gene editing, and DNA vaccines.
Dr. Heikki Lanckriet, CEO and CSO for 4basebio, highlighted the company's significant progress, stating, "Having scaled its DNA manufacturing from nanogram to multi-gram scale over this time, 4basebio fulfilled over 25 customer projects in 2023." He also mentioned the company's involvement in the manufacture of a client's mRNA vaccine product for first-in-human trials in Australia and the supply of HQ and GMP grade synthetic DNA into a tier one pharma company's vaccine program.
The company's chairman emphasized the significant milestones achieved in 2023, particularly the sale of its first High-Quality DNA and the receipt of orders for GMP grade product due for delivery in 2024. 4basebio also received grant funding from the Bill & Melinda Gates Foundation to advance its nanoparticle platform with enhanced thermostability for use in infectious disease vaccine applications, addressing logistical challenges and cost considerations in vaccine distribution.
Furthermore, the company continued to invest in its intellectual property, filing six new patent applications in 2023 and early 2024, bringing the total to 17 patent families around its DNA platform and four patent families centered on its Hermes™ technology. The company has also pursued legal action in Spain to protect its intellectual property.
Overall, 4basebio Plc is on the verge of strong commercial growth, with 2024 expected to be an exciting year for the company as it continues to expand its commercial platform and invest in research and development activities to further develop its platforms and product offerings.